Overview on Hormonal Replacement Therapy in Menopause

Shaden Akram A. Alanazi *

University of Tabuk, Saudi Arabia.

Atheer Mansour E. Alatawi

University of Tabuk, Saudi Arabia.

Atheer Salman O. Alhwaiti

University of Tabuk, Saudi Arabia.

Aumniyat Saad A. Alrashidi

University of Tabuk, Saudi Arabia.

Dimah Mohammed A. Abu Murad

University of Tabuk, Saudi Arabia.

Ghadah Ali R. Alanazi

University of Tabuk, Saudi Arabia.

Mei Khalid S. Alfaqiri

University of Tabuk, Saudi Arabia.

Rahaf Naif A. Alenezi

University of Tabuk, Saudi Arabia.

Wejdan Abdullah Albalawi

University of Tabuk, Saudi Arabia.

Layan Hussain J. Alharbi

University of Tabuk, Saudi Arabia.

*Author to whom correspondence should be addressed.


Abstract

Hormone replacement therapy (HRT) is defined as a therapy that could allow women to free themselves from the malediction of estrogen loss and conserve their femininity. The study aims to summarize the updated evidence regards types, indication, contraindication, and untoward effects of hormonal replacement therapy among menopausal women. There are several different drug classes comprising estrogens, progestogens, and estrogen + progestogen combinations. Estrogen is the primary active component of HRT, treating menopausal symptoms, particularly vasomotor symptoms. There are several adverse effects of hormone replacement therapy that manifest in many different ways depending on the route of administration, and whether that route has local or systemic effects. Further research is needed to study the risks of menopausal HRT and pharmacological studies are needed to lower these risks and make its use safer with less side effects.

Keywords: Menopause, hormone replacement therapy, estrogens, progestogens, estrogen and progestogen combinations


How to Cite

Alanazi, S. A. A., Alatawi, A. M. E., Alhwaiti, A. S. O., Alrashidi, A. S. A., Murad, D. M. A. A., Alanazi, G. A. R., Alfaqiri, M. K. S., Alenezi, R. N. A., Albalawi, W. A. and Alharbi, L. H. J. (2021) “Overview on Hormonal Replacement Therapy in Menopause”, Journal of Pharmaceutical Research International, 33(39A), pp. 141–147. doi: 10.9734/jpri/2021/v33i39A32152.